Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

NCT07492342 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Resectable NSCLC
KRAS G12C Mutation
Stage IB-IIIA NSCLC
Neoadjuvant Therapy

Interventions

DRUG: fulzerasib

Sponsor

Jianxing He

Collaborators

[object Object]